
About Ilico Genetics
Ilico Genetics is a Healthcare company based in Bethlehem (United States) founded in 2020 by Fernando Alarcon Hardy, Alejandro Corvalan, and Maria Maturana. Developer of diagostic test for detection of gastric cancer. Ilico Genetics has raised $457.74 thousand across 1 funding round. Its chief executive, as recorded, is Fernando Alarcon Hardy. Ilico Genetics offers products and services including Stomach Cancer Screening Test. Its focus areas include Life Sciences, Gastroenterology, In Vitro Diagnostic Tests and Gastrointestinal Cancer. Its competitors include Intima Bioscience, TLR Therapeutics and Kupffer Biotherapeutics.
Company details
Ilico Genetics was founded in 2020 in Bethlehem, United States, within the biotechnology sector. Diagnostic tests for gastric cancer are developed, focusing on molecular analysis of methylated DNA obtained from blood samples. Tumors or lesions in the stomach are detected through this non-invasive method. Operations center on advancing early detection technologies for oncology applications in the diagnostic industry.
- Headquarters Bethlehem, United States
- Founders Fernando Alarcon Hardy, Alejandro Corvalan, Maria Maturana
- SectorsHealthcare
- Website ilicogenetics.com
- Social LinkedIn Facebook Instagram YouTube
- Total Equity Funding$457.74K (USD)
in 1 rounds
- Latest Funding Round$457.74K (USD), Seed
Oct 2023
Products & Services of Ilico Genetics
Ilico Genetics offers a comprehensive portfolio of products and services, including Stomach Cancer Screening Test.
Blood test to detect early-stage gastric cancer before symptoms.
Apps and channels of Ilico Genetics
its YouTube channel Ilico Genetics has 1 subscribers.
Funding Insights of Ilico Genetics
Ilico Genetics has successfully raised a total of $457.74K through 1 strategic funding round. The most recent funding activity was a Seed round of $457.74 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $457,735
- Total Rounds 1
- Last Round Seed β $457,735
- First Round $457,735
(Oct 2023)
All 1 funding rounds of Ilico Genetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $457,735 | Seed | β | β | β |
People of Ilico Genetics
5 people are tracked at Ilico Genetics (5 in leadership).
| Name | Role | Group |
|---|---|---|
Fernando Alarcon Hardy | Co-Founder & CEO | Leadership |
Alejandro Corvalan | Co-Founder | Leadership |
Maria Maturana | Co-Founder | Leadership |
Maria Jose Maturana Rojas | Co-founder & COO | Leadership |
Fernando Alarcon | Co-founder & CEO | Leadership |
Complete people profiles for Ilico Genetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ilico Genetics
2 dated milestones of Ilico Genetics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Ilico Genetics is founded.
- Funding First funding round of $458K.
Competitors of Ilico Genetics
Ilico Genetics has 3 listed competitors in our database. They include Intima Bioscience, TLR Therapeutics and Kupffer Biotherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| intimabioscience.com | 2014 | New York, United States | Therapeutics for gastrointestinal cancer are developed using CRISPR gene-editing. | |||
| tlrtx.com | 2022 | Wilmington, United States | Develops innovative therapeutics for treating myelodysplastic syndrome and gastric cancer. | |||
| kupfferbio.com | 2019 | Burlingame, United States | Develops innovative technologies for anticancer therapies targeting gastrointestinal cancers. |
Detailed competitors of Ilico Genetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Ilico Genetics (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ilico Genetics
Ilico Genetics was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Ilico Genetics is headquartered in Bethlehem, United States.
Fernando Alarcon Hardy is the CEO of Ilico Genetics, as recorded in our data. They have also founded this company.
Ilico Genetics is a funded company, having raised a total of $457.74K across 1 funding round to date. The company's 1st funding round was a Seed of $457.74K, raised on Oct 2023.
Ilico Genetics was founded in 2020 in Bethlehem, United States, within the biotechnology sector. Diagnostic tests for gastric cancer are developed, focusing on molecular analysis of methylated DNA obtained from blood samples. Tumors or lesions in the stomach are detected through this non-invasive method. Operations center on advancing early detection technologies for oncology applications in the diagnostic industry.
Ilico Genetics's top competitors include Intima Bioscience, TLR Therapeutics and Kupffer Biotherapeutics.
Ilico Genetics offers Stomach Cancer Screening Test.